M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate Pharmaceutical TechnologyThe deal provides BioMarin with a potential rival to AstraZeneca's blockbuster Strensiq in hypophosphatasia.Rare DiseaseRead full story pharminent August 19, 2026 (Last updated: August 23, 2026) Pharmaceutical Technology The deal provides BioMarin with a potential rival to AstraZeneca’s blockbuster Strensiq in hypophosphatasia. Rare Disease Read full story Post navigation Previous: Amylyx’s Avexitide Succeeds in Phase 3 Pivotal Study for Post-Bariatric HypoglycemiaNext: Trump nominates policy aide Overton to lead FDA Related Stories M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026 M&A / Deals Sandoz targets industry patent void with $322m Henlius deal pharminent August 17, 2026
